Total Payments
$23,206
2024 Payments
$3,962
Companies
83
Transactions
1,305
Medicare Patients
43,119
Medicare Billing
$12.7M
Payment Breakdown by Category
Food & Beverage$22,694 (97.8%)
Education$512.84 (2.2%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $22,694 | 1,289 | 97.8% |
| Education | $512.84 | 16 | 2.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,932 | 121 | $0 (2024) |
| Janssen Biotech, Inc. | $1,725 | 113 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $1,720 | 117 | $0 (2024) |
| Merck Sharp & Dohme LLC | $1,483 | 74 | $0 (2024) |
| Celgene Corporation | $1,096 | 55 | $0 (2024) |
| GENZYME CORPORATION | $1,032 | 40 | $0 (2024) |
| Genentech USA, Inc. | $927.51 | 60 | $0 (2024) |
| Amgen Inc. | $921.71 | 48 | $0 (2022) |
| Incyte Corporation | $891.65 | 41 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $890.25 | 43 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,962 | 189 | Novartis Pharmaceuticals Corporation ($330.55) |
| 2023 | $3,019 | 143 | Novartis Pharmaceuticals Corporation ($276.51) |
| 2022 | $2,931 | 155 | Celgene Corporation ($252.04) |
| 2021 | $2,838 | 149 | Janssen Biotech, Inc. ($275.79) |
| 2020 | $2,330 | 145 | E.R. Squibb & Sons, L.L.C. ($261.89) |
| 2019 | $3,328 | 183 | Novartis Pharmaceuticals Corporation ($391.79) |
| 2018 | $2,511 | 158 | Novartis Pharmaceuticals Corporation ($414.84) |
| 2017 | $2,287 | 183 | Novartis Pharmaceuticals Corporation ($335.25) |
All Payment Transactions
1,305 individual payment records from CMS Open Payments — Page 1 of 53
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $26.35 | General |
| Category: Hematology | ||||||
| 12/19/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $13.75 | General |
| Category: Oncology | ||||||
| 12/18/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $18.95 | General |
| Category: Oncology | ||||||
| 12/18/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $9.64 | General |
| Category: Oncology | ||||||
| 12/17/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $15.30 | General |
| 12/12/2024 | Bayer Healthcare Pharmaceuticals Inc. | Stivarga (Drug), Vitrakvi, Nubeqa | Food and Beverage | In-kind items and services | $21.24 | General |
| Category: Oncology | ||||||
| 12/09/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $28.59 | General |
| Category: ONCOLOGY | ||||||
| 12/05/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $23.16 | General |
| Category: Hematology | ||||||
| 12/04/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $17.79 | General |
| Category: Rare Disease | ||||||
| 12/03/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $33.91 | General |
| Category: Oncology | ||||||
| 12/02/2024 | Lilly USA, LLC | VERZENIO (Drug), RETEVMO, JAYPIRCA | Food and Beverage | In-kind items and services | $32.37 | General |
| Category: Oncology | ||||||
| 11/25/2024 | E.R. Squibb & Sons, L.L.C. | KRAZATI (Drug) | Food and Beverage | Cash or cash equivalent | $16.49 | General |
| Category: Oncology | ||||||
| 11/21/2024 | Genentech USA, Inc. | Polivy (Biological) | Food and Beverage | In-kind items and services | $19.96 | General |
| Category: BioOncology | ||||||
| 11/19/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $21.86 | General |
| Category: Oncology | ||||||
| 11/14/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI, TUKYSA | Food and Beverage | In-kind items and services | $14.01 | General |
| Category: ONCOLOGY | ||||||
| 11/12/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $18.55 | General |
| Category: ONCOLOGY | ||||||
| 11/12/2024 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $18.18 | General |
| Category: CELLT | ||||||
| 11/07/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $28.60 | General |
| Category: Hematology | ||||||
| 11/06/2024 | Pharmacosmos Therapeutics Inc. | MONOFERRIC (Drug) | Food and Beverage | In-kind items and services | $25.20 | General |
| Category: HEMATOLOGY | ||||||
| 10/28/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI, TUKYSA | Food and Beverage | In-kind items and services | $16.88 | General |
| Category: ONCOLOGY | ||||||
| 10/24/2024 | Tempus AI, Inc | XT CDX (Device) | Food and Beverage | In-kind items and services | $26.49 | General |
| Category: NONE | ||||||
| 10/23/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $18.66 | General |
| Category: ONCOLOGY | ||||||
| 10/22/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $26.59 | General |
| Category: Oncology | ||||||
| 10/21/2024 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $24.74 | General |
| Category: CELLT | ||||||
| 10/18/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $15.59 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 51 | 5,988 | 253,844 | $8.6M | $2.5M |
| 2022 | 84 | 9,860 | 324,700 | $9.8M | $2.8M |
| 2021 | 95 | 13,122 | 433,782 | $10.9M | $3.3M |
| 2020 | 104 | 14,149 | 542,716 | $13.5M | $4.2M |
Total Patients
43,119
Total Services
1,555,042
Medicare Billing
$12.7M
Procedure Codes
334
All Medicare Procedures & Services
334 procedure records from CMS Medicare Utilization — Page 1 of 14
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 23 | 31,200 | $4.3M | $1.3M | 31.5% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 117 | 17,400 | $887,400 | $321,223 | 36.2% |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 2023 | 15 | 7,446 | $804,168 | $265,855 | 33.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 920 | 2,455 | $586,745 | $163,143 | 27.8% |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 2023 | 52 | 11,270 | $259,210 | $65,933 | 25.4% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 98 | 518 | $195,804 | $49,507 | 25.3% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 1,151 | 3,674 | $33,066 | $30,807 | 93.2% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 1,109 | 3,880 | $112,520 | $29,480 | 26.2% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 166 | 599 | $113,211 | $27,695 | 24.5% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 435 | 2,499 | $172,431 | $25,040 | 14.5% |
| J1437 | Injection, ferric derisomaltose, 10 mg | Office | 2023 | 14 | 1,400 | $79,800 | $23,122 | 29.0% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 151 | 156 | $58,812 | $16,110 | 27.4% |
| J0185 | Injection, aprepitant, 1 mg | Office | 2023 | 24 | 10,790 | $53,950 | $14,747 | 27.3% |
| J1756 | Injection, iron sucrose, 1 mg | Office | 2023 | 80 | 67,700 | $338,500 | $10,815 | 3.2% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 96 | 778 | $47,458 | $8,923 | 18.8% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 104 | 104 | $30,992 | $8,455 | 27.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 77 | 84 | $28,476 | $8,090 | 28.4% |
| Q5101 | Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | Office | 2023 | 25 | 47,040 | $94,080 | $8,057 | 8.6% |
| G0498 | Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | Office | 2023 | 12 | 59 | $37,583 | $7,494 | 19.9% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 76 | 104 | $20,488 | $6,510 | 31.8% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2023 | 21 | 15,810 | $63,240 | $6,196 | 9.8% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 27 | 121 | $21,538 | $5,876 | 27.3% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2023 | 30 | 319 | $17,864 | $4,869 | 27.3% |
| 96374 | Injection of drug or substance into vein | Office | 2023 | 74 | 146 | $22,776 | $3,878 | 17.0% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 15 | 69 | $14,214 | $3,708 | 26.1% |
About Dr. Sandeep Thaper, M.D
Dr. Sandeep Thaper, M.D is a Hematology healthcare provider based in Leesburg, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/09/2006. The National Provider Identifier (NPI) number assigned to this provider is 1881627966.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Sandeep Thaper, M.D has received a total of $23,206 in payments from pharmaceutical and medical device companies, with $3,962 received in 2024. These payments were reported across 1,305 transactions from 83 companies. The most common payment nature is "Food and Beverage" ($22,694).
As a Medicare-enrolled provider, Thaper has provided services to 43,119 Medicare beneficiaries, totaling 1,555,042 services with total Medicare billing of $12.7M. Data is available for 4 years (2020–2023), covering 334 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology
- Other Specialties Medical Oncology
- Location Leesburg, FL
- Active Since 07/09/2006
- Last Updated 09/02/2022
- Taxonomy Code 207RH0000X
- Entity Type Individual
- NPI Number 1881627966
Products in Payments
- KEYTRUDA (Biological) $1,392
- OPDIVO (Biological) $1,385
- IMBRUVICA (Drug) $1,205
- JAKAFI (Drug) $574.24
- DARZALEX (Biological) $477.27
- REBLOZYL (Biological) $460.83
- Lenvima (Drug) $446.17
- KISQALI (Drug) $394.74
- SARCLISA (Biological) $361.43
- MONJUVI (Drug) $342.78
- TASIGNA (Drug) $332.87
- LIBTAYO (Biological) $292.94
- Enhertu (Drug) $288.77
- FOUNDATIONONE (Device) $284.82
- IMFINZI (Biological) $276.95
- ZEJULA (Drug) $267.60
- MEKINIST (Drug) $262.15
- XTANDI (Drug) $256.12
- ADCETRIS (Biological) $256.04
- Nplate (Biological) $248.79
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.